ELN and neoplasm: Especially in the area of targeted therapies of tumor associated ECM components or cancer to stroma signaling cross-talks, such as sorafenib and erlotinib, elastin-specific molecular imaging could act as a potential imaging biomarker to demonstrate the tumor responsiveness to the therapeutic agent.